Auna Announces 1Q24 Financial Results Revenue increases 20% YoY to S/1,076 million, with operating profit increasing 26% to S/182 million Adjusted EBITDA margin of 20.4% in Peruvian operations Luxembourg

Announces 1Q24 Financial Results

Revenue increases 20% YoY to

S/1,076 million, with operating profit increasing 26% to S/182 million

Adjusted EBITDA margin of 20.4%

in Peruvian operations

Luxembourg, May 22, 2024 - Auna (NYSE:

AUNA) ("Auna" or the "Company"), one of the largest and most recognized company in Latin America's healthcare

industry with operations in Mexico, Colombia and Peru, today announced unaudited financial results for the three months ended March 31,

2024 ("first quarter 2024" or "1Q24").

Financial results are expressed in Peruvian Soles

("S/" or PEN") and are presented in accordance with International Financial Reporting Standards ("IFRS"),

unless otherwise noted. Figures in US dollars (US$ or USD) for 1Q24 are presented for indicative purposes and were calculated using an

FX rate of US$1= S/3.718. All comparisons in this announcement are year-over-year ("YoY"), unless otherwise noted; additionally,

results are presented in an FX neutral basis ("FXN") for consolidated revenues, consolidated cost of sales and services, consolidated

selling and administrative expenses and consolidated adjusted EBITDA, as well as, in local currency for the Mexico and Colombia segments,

to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods.

Financial results are preliminary and subject to

year-end audit and adjustments.

1Q24 Consolidated Financial Highlights

Message from Auna's Executive

Chairman and President

"Guided by strong leadership in our clinical,

technology and business teams across Auna, our regional, horizontally and vertically integrated healthcare platform delivered strong results

in the first quarter. Our 20% consolidated revenue growth was the main driver of the 26% YoY increase in our operating profit and 14%

increase in Adjusted EBITDA.

Importantly, Peru reached our target Adjusted EBITDA

of 20%. As our continued success in Peru makes clear, we are capable of generating substantial returns as our capacity utilization rises.

This strengthens our conviction in Mexico, where we are committed to deploying the same integrated business model. Accordingly, we continue

to invest in bringing our operations in Monterrey up to AunaWay standards and in hiring top talent, both essential to expanding our high-complexity

services and ramping up capacity utilization in Monterrey's fast-growing market. Our recent performance at our OCA network in Monterrey

is encouraging, with Adjusted EBITDA increasing 34% versus Q423 in local currency. We are also investing in the planned launch of OncoMexico

later this year, with the intention of fully leveraging the nationwide insurance license and extensive distribution network that we gained

through the acquisition of Dentegra last year.

As we continue to build our capabilities in Mexico,

we expect returns to strengthen in the latter half of the year, giving us the ability to improve our financial position by reducing absolute

debt levels and our leverage ratio.

To expand on our outlook for the remainder of 2024,

we expect Adjusted EBITDA to increase 20% or more versus 2023. We remain confident in our ability to disrupt, modernize and integrate

healthcare in Spanish Speaking Latin America, delivering strong value creation for Auna's stakeholders. Of course, that would not

be possible without the many doctors, nurses, technicians, managers and other colleagues dedicated to our mission of transforming healthcare

Key Financial and Operating Metrics

(Figures in millions of Soles

and millions of US Dollars, unless expressed otherwise)

2024 Financial Guidance

Guidance: For full-year 2024, the Company

expects consolidated Adjusted EBITDA to increase at least 20% YoY on an FX-neutral basis.

Assumptions: Auna s guidance is based

on management's current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the

Company operates. Any changes in these conditions could have an impact on the guidance provided.

Disclaimer: The 2024 financial

guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict,

including those discussed in the Risk Factors set forth in the Company's Form F-1 filed with the United States Securities and Exchange

Commission (the "SEC"). Reconciliations of forward-looking non-IFRS measures, specifically the 2024 EBITDA guidance, to the

relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate

the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile

projected EBITDA to projected net income without unreasonable effort. The 2024 financial guidance constitutes forward-looking statements.

For more information, see the "Forward-Looking Statements" section in this release.

Overview of 1Q24 Results

Factors Impacting YoY Comparability

The following factors should be considered when

comparing Auna s 1Q24 financial and operating results with those of 1Q23:

Consolidated revenues increased 20% YoY

to S/1,076 million, or 11% FXN. In Mexico, revenue increased 5% in FXN, reflecting 5% growth in the number of patients treated. In Colombia,

revenue increased 15% in FXN, reflecting a prioritization of higher-margin oncology services, resulting in a 22% increase in average ticket.

Overall, the growth was mainly driven by very strong performance of the Peruvian Healthcare Services and Oncosalud segments, which reported

revenue increases of 14% and 15%, respectively. The performance of Peruvian Healthcare Services reflects the ramp-up of facilities, including

expansions at Vallesur, Delgado and the organic development of Cl nica Chiclayo, an increased focus on high-complexity services,

and the rebalancing of medical specialties across Auna's facilities, while Oncosalud saw a 6% increase in healthcare plan members

and a 3.5% increase in average ticket per oncological membership.

Cost of Sales and Services increased S/96

million, or 17%, YoY to S/662 million. 1Q24 includes headcount reclassifications and depreciation effects in Mexico; excluding these effects

and the FX impact, the increase would have been 12% FXN, in line with FXN revenue growth. Growth in costs supported a higher volume of

high-complexity treatments in the Colombia and Peru Healthcare networks, and in Oncosalud, as well as salary adjustments to Auna's

Gross profit increased 26% YoY to S/414

million, with a 38.5% gross margin.

Selling, General & Administrative expenses

were S/244 million, an increase of 29% YoY. SG&A represented 23% of consolidated revenues versus 21% in 1Q23. The increase in SG&A

partially reflects the abovementioned headcount reclassification from cost of sales and services. When excluding this reclassification

and adjusting for FX impact, SG&A increased 15% FXN YoY. The remaining increase was mainly due to the expansion of regional capabilities

to deliver strategic growth in the medium to long term. Over the past year, Auna completed its transition to a regional structure, focused

both on strategic long-term capabilities in Healthcare Services and Access (our healthcare plans) as well as on regional, commercial and

operational capabilities. This transition, coupled with building local, operating and administrative capabilities in Mexico, is necessary

to fully implement the AunaWay in order to reach the standards required to deliver sustainable and profitable growth.

Operating Profit was S/182 million, an increase

of 26% YoY and 39% QoQ primarily the result of strong revenue growth in the Peru and Colombia segments and supporting variable costs related

to a greater mix of high-complexity services and expenses related to the implementation of strategic capabilities in Mexico.

Net finance cost increased 38% YoY, or S/46

million, to S/168 million.

In December 2023, the refinancing process not only

generated extraordinary impacts, as a result of prepayments, but also non-cash mark-to-market impacts of a USD/MXN derivative no longer

necessary, given the change from USD to direct local funding in MXN, going from USD 396.5 million to USD 125 million by 4Q 2023, and to

US$30 million by 1Q 2024.

In 4Q23, these extraordinary impacts totaled S/216

million and were related to pre-payment fees, transaction costs and mark-to-market derivative valuations.

For 1Q24, net finance cost increased 38% YoY, or

S/46 million, to S/168 million, and included an additional non-cash extraordinary financial cost of S/30 million related to the mark-to-market

of the above-mentioned derivative. Excluding this non-cash extraordinary item, net interest cost was S/ 138 million.

Net Income (loss) reflected a loss for 1Q24

of S/8 million, compared to a Net Loss of S/219 million in 4Q23 and breakeven in 1Q23. Operating profit of S/182 million, which increased